Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10908919 | Leukemia Research | 2014 | 6 Pages |
Abstract
Total therapy 3 is an intensified protocol for multiple myeloma (MM). The “real life” outcomes of this protocol were seldom reported. Data was obtained for 81 patients (newly diagnosed, n = 49; progressive MM, n = 32), most of which had high-risk parameters. Overall response rate following (V)DT-PACE was 96% and 75% for the newly diagnosed and progressive groups, respectively. Median progression-free survival was 42.5 and 9 months, respectively. The 2-year overall survival was 88% and 40%, respectively. Treatment with (V)DT-PACE achieves high response rate among patients with high-risk disease, which can be translated into long-term remission only for newly diagnosed patients.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eli Muchtar, Ron Ram, Pia Raanani, Moshe Yeshurun, Nino Oniashvili, Ofer Shpilberg, Hila Magen,